Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab

Overview of attention for article published in HEPAC Health Economics in Prevention and Care, June 2011

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (69th percentile)
Above-average Attention Score compared to outputs of the same age and source (53rd percentile)

Mentioned by

policy: 1 policy source

twitter: 2 X users

Citations

dimensions_citation: 21 Dimensions

Readers on

mendeley: 84 Mendeley

Summary Policy documents X Dimensions citations

So far, Altmetric has seen 1 policy document that references this research output.

Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies : Committee papers

Cited by National Institute for Health and Care Excellence on 12 Apr 2021

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.